Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NT 501

Drug Profile

NT 501

Alternative Names: Ciliary neurotrophic factor - Neurotech; Ciliary neurotrophic factor implant - Neurotech; CNTF implant - Neurotech; Encapsulated CNTF - Neurotech; NT-501; Retinitis pigmentosa encapsulated cell therapy - Neurotech; Rexenus

Latest Information Update: 22 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Neurotech USA
  • Developer National Eye Institute; Neurotech USA; Stanford University; University of Miami
  • Class Cell therapies; Eye disorder therapies
  • Mechanism of Action Ciliary neurotrophic factor replacements; Neurogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinal telangiectasis; Retinitis pigmentosa
  • New Molecular Entity No

Highest Development Phases

  • Phase III Retinal telangiectasis
  • Phase II/III Retinitis pigmentosa
  • Phase II Glaucoma; Usher syndromes
  • Phase I/II Colour vision defects
  • No development reported Dry macular degeneration; Optic nerve disorders

Most Recent Events

  • 20 Nov 2018 Neurotech Pharmaceuticals initiates enrolment in the phase III trial for Retinal telangiectasis in Australia, United Kingdom and USA (Intraocular) (EudraCT2017-003234-82) (NCT03316300)
  • 05 Oct 2018 Phase-III clinical trials in Retinal telangiectasis in France (Intraocular) (EudraCT2017-003234-82) (NCT03316300)
  • 02 Oct 2018 Phase-III clinical trials in Retinal telangiectasis in Germany (Intraocular) (EudraCT2017-003260-12)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top